Malus Sylvestris Flower

Dosage for Malus Sylvestris Flower is highly individualized and depends entirely on the purpose of administration (diagnostic vs. therapeutic).

Diagnostic Dosage (Skin Prick Test)

For diagnostic purposes, a single drop of the non-standardized extract (typically at a concentration of 1:10 or 1:20 w/v) is applied to the skin, usually on the forearm or back. A sterile lancet is then used to prick the skin through the drop. The results are interpreted 15 to 20 minutes later.

Immunotherapy Dosage (SCIT)

If used for desensitization, the dosage follows a 'build-up' phase and a 'maintenance' phase:

• Build-up Phase: Starts with a very low dose (e.g., 0.05 mL of a 1:10,000 dilution) injected subcutaneously once or twice weekly. The dose is gradually increased over 3 to 6 months.
• Maintenance Phase: Once the target dose is reached (e.g., 0.5 mL of a 1:10 or 1:20 dilution), the frequency of injections is reduced to once every 4 to 6 weeks. This phase typically continues for 3 to 5 years.

Malus Sylvestris Flower extracts can be used in children, but caution is required.

• Skin Testing: Safe for use in children as young as infants, though reactivity may be lower in children under 2 years of age.
• Immunotherapy: Generally not recommended for children under the age of 5 due to the difficulty of communicating symptoms of a systemic reaction. For children over 5, the dosage is typically the same as the adult dosage but must be administered with extreme caution by a pediatric allergist.

Renal Impairment

No specific dosage adjustments are provided for renal impairment, as the systemic absorption of diagnostic extracts is minimal. However, in immunotherapy, patients with severe renal disease should be monitored closely for their ability to handle systemic stress if a reaction occurs.

Hepatic Impairment

No adjustments are required for patients with liver disease, as the metabolism of allergenic proteins does not rely on hepatic CYP450 pathways.

Elderly Patients

Elderly patients (over 65) may have reduced skin reactivity, leading to potential false-negative results in skin testing. Furthermore, elderly patients are at higher risk for complications if they require epinephrine to treat an allergic reaction; therefore, the lowest effective dose should be used during testing.

Malus Sylvestris Flower extract is not for self-administration in its clinical extract form. It must be administered by a healthcare professional trained in allergy management.

• Preparation: The skin site (usually the volar surface of the forearm) should be cleaned with alcohol and allowed to dry.
• Controls: A positive control (histamine) and a negative control (saline) must be administered alongside the Malus Sylvestris extract to ensure the validity of the test.
• Storage: Vials must be stored in a refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze, as freezing can denature the allergenic proteins and render the extract ineffective.

In the context of immunotherapy, a missed dose can disrupt the desensitization process:

• 1-2 weeks late: Usually, the same dose can be given.
• 3-4 weeks late: The dose may need to be reduced by one or two steps to prevent a reaction.
• Over 4 weeks late: The build-up phase may need to be restarted at a much lower concentration.

An 'overdose' of Malus Sylvestris Flower extract usually refers to an accidental injection of too much allergen or an injection given too frequently.

• Signs: Rapid onset of hives, swelling of the throat, wheezing, drop in blood pressure, and anaphylaxis.
• Emergency Measures: Immediate administration of epinephrine (0.3 mg for adults), followed by antihistamines, corticosteroids, and emergency transport to a hospital.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance.

The most common side effects of Malus Sylvestris Flower occur locally at the site of administration. These are often expected results of diagnostic testing:

• Local Wheal: A raised, itchy bump at the test site. It usually peaks at 20 minutes and resolves within 2 hours.
• Erythema (Flare): Redness surrounding the test site, which may feel warm to the touch.
• Pruritus (Itching): Intense itching at the site of the skin prick or injection.
• Local Swelling: In immunotherapy, a 'late-phase' swelling may occur 6 to 12 hours after the injection, sometimes involving the entire upper arm.

These reactions are more systemic in nature and may indicate a higher level of sensitivity:

• Generalized Urticaria (Hives): Itchy red welts appearing on parts of the body away from the injection site.
• Nasal Congestion: Sneezing or a runny nose shortly after exposure to the extract.
• Ocular Itching: Red, watery, or itchy eyes (allergic conjunctivitis).
• Fatigue: A feeling of tiredness or 'brain fog' following a strong allergic reaction or immunotherapy session.

• Angioedema: Deep tissue swelling, most commonly affecting the lips, eyelids, or tongue.
• Gastrointestinal Distress: Nausea, abdominal cramping, or diarrhea, which can be a sign of a systemic IgE-mediated reaction.
• Vasovagal Response: Fainting or lightheadedness, often due to the stress of the needle prick rather than the extract itself.

> Warning: Stop taking Malus Sylvestris Flower and call your doctor immediately if you experience any of these.

• Anaphylaxis: A life-threatening, multi-system allergic reaction. Symptoms include a sudden drop in blood pressure (shock), rapid pulse, and fainting.
• Bronchospasm: Difficulty breathing, wheezing, or a tight feeling in the chest. This is particularly dangerous in patients with pre-existing asthma.
• Laryngeal Edema: Swelling of the throat or 'lump in the throat' feeling, which can obstruct the airway.
• Cyanosis: A bluish tint to the lips or fingernails, indicating a lack of oxygen.

With prolonged use in immunotherapy, Malus Sylvestris Flower is generally well-tolerated. However, long-term risks include:

• Persistent Injection Site Granuloma: A small, hard knot under the skin that persists for months.
• Shift in Immune Profile: While the goal is to increase IgG4 (protective antibodies), some patients may develop new sensitivities to other components in the extract over several years.

While Malus Sylvestris Flower itself may not have a specific individual black box warning, all Allergenic Extracts as a class carry a general warning regarding the risk of severe anaphylaxis.

Class Warning Summary: Allergenic extracts can cause severe life-threatening systemic reactions, including anaphylaxis. Patients must be observed for at least 30 minutes following administration. These products should only be administered by healthcare providers equipped with emergency equipment and medications (e.g., epinephrine) to treat anaphylaxis.

Report any unusual symptoms to your healthcare provider.

Malus Sylvestris Flower extract is a potent biological agent. Its use is strictly limited to clinical settings where emergency resuscitation equipment is available. Patients must inform their provider of any history of severe asthma, as this significantly increases the risk of a fatal reaction to allergenic extracts.

No specific FDA black box warning exists specifically for Malus Sylvestris Flower, but it is governed by the general Allergenic Extracts Class Warning. This warning emphasizes that these products are intended for use only by physicians experienced in the diagnosis and treatment of allergic diseases. It mandates that patients be observed for a minimum of 30 minutes after any injection to monitor for systemic reactions.

• Allergic Reactions / Anaphylaxis Risk: This is the primary concern. Even patients who have previously tolerated the extract may suddenly experience a severe reaction. Risk factors include high pollen counts in the environment at the time of injection and exercise shortly after administration.
• Asthma Stability: Patients with unstable or poorly controlled asthma should not undergo testing or immunotherapy with Malus Sylvestris Flower. A flare-up of asthma during an allergic reaction to the extract can be fatal.
• Beta-Blocker Use: Patients taking beta-blockers (for blood pressure or heart conditions) are at higher risk because these drugs can make anaphylaxis more severe and make the patient resistant to the effects of epinephrine.
• Cardiovascular Disease: Patients with severe heart disease may not be able to tolerate the hemodynamic stress of a systemic reaction or the effects of the epinephrine used to treat it.

• Observation Period: A strict 30-minute post-administration wait time is mandatory.
• Lung Function: For patients with asthma, a peak flow or spirometry test may be performed before administration to ensure the patient is at their baseline.
• Skin Site Inspection: The site of administration must be checked for excessive local reactions (greater than 5-10 cm) which may necessitate a dose reduction for future treatments.

Malus Sylvestris Flower generally does not cause drowsiness. However, if a patient experiences a systemic reaction or receives epinephrine, they should not drive or operate machinery until they have fully recovered and been cleared by a medical professional.

Alcohol should be avoided for at least 24 hours before and after administration. Alcohol causes vasodilation (widening of blood vessels), which can increase the rate of allergen absorption and potentially trigger or worsen an allergic reaction.

In diagnostic testing, the 'discontinuation' simply involves the resolution of the skin test. In immunotherapy, stopping the treatment suddenly will not cause 'withdrawal' in the traditional sense, but it will result in the gradual return of the patient's original allergy symptoms. Tapering is not required.

> Important: Discuss all your medical conditions with your healthcare provider before starting Malus Sylvestris Flower.

• Beta-Blockers (e.g., Propranolol, Atenolol): These are contraindicated in patients receiving allergenic extracts for immunotherapy. They block the receptors that epinephrine needs to work, making a life-threatening reaction much harder to treat.
• ACE Inhibitors (e.g., Lisinopril): Some evidence suggests ACE inhibitors may increase the risk of severe systemic reactions to allergenic extracts and may interfere with the body's natural compensatory mechanisms during shock.

• MAO Inhibitors (e.g., Phenelzine): These can potentiate the effects of epinephrine, leading to dangerously high blood pressure if an emergency occurs and epinephrine must be administered.
• Tricyclic Antidepressants (e.g., Amitriptyline): Similar to MAOIs, these can increase the cardiovascular response to epinephrine, requiring cautious use during emergency situations.

• Antihistamines (e.g., Loratadine, Cetirizine): These must be discontinued 3 to 7 days before skin testing. They block the H1 receptors, preventing the 'wheal and flare' reaction and leading to a false-negative diagnostic result.
• H2 Blockers (e.g., Famotidine): These may also suppress skin reactivity and should be discontinued at least 48 hours before testing.
• Topical Corticosteroids: If applied to the test site, these will suppress the local inflammatory response and invalidate the test results.

• Cross-Reactive Foods: Patients sensitive to Malus Sylvestris Flower often have 'Oral Allergy Syndrome.' Eating raw apples, pears, or cherries shortly before or after testing can prime the immune system and increase the likelihood of a systemic reaction.
• Alcohol: As mentioned, alcohol increases systemic absorption and should be avoided.

• High-Dose Vitamin C: While Malus Sylvestris is classified under Vitamin C [EPC], taking additional high-dose Vitamin C supplements may theoretically have a mild antihistamine effect, potentially dampening skin test results.
• Astragalus or Echinacea: These immune-stimulating herbs may theoretically alter the immune response to the extract, though clinical data is lacking.

• Skin Testing: The presence of the extract in the skin will interfere with any other dermatological tests being performed in the same area.
• Serum IgE: Administration of the extract (especially in immunotherapy) will cause a transient rise in total and specific serum IgE levels, which may complicate the interpretation of blood-based allergy tests (like RAST or ImmunoCAP).

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking.

• Severe, Uncontrolled Asthma: Patients with an FEV1 (Forced Expiratory Volume) consistently below 70% of predicted values are at an unacceptably high risk for fatal bronchospasm during a reaction.
• Recent Myocardial Infarction (Heart Attack): Within the last 3-6 months. The heart may not be able to withstand the stress of anaphylaxis or the administration of epinephrine.
• Previous Severe Systemic Reaction: Any patient who has had a life-threatening reaction to Malus Sylvestris Flower in the past should not be re-exposed unless in an extremely controlled hospital setting.
• Beta-Blocker Therapy: As noted, the inability to respond to epinephrine is a major contraindication for ongoing immunotherapy.

• Pregnancy: While not strictly contraindicated for those already on a maintenance dose, starting new immunotherapy or performing skin tests during pregnancy is generally avoided due to the risk of fetal hypoxia (lack of oxygen) during a maternal systemic reaction.
• Autoimmune Diseases: Conditions like Lupus or Rheumatoid Arthritis may be exacerbated by the immune-modulating effects of allergenic extracts.
• Malignancy: Patients with active cancer may have altered immune systems that make the results of testing or the safety of immunotherapy unpredictable.

Patients allergic to Malus Sylvestris Flower frequently show cross-sensitivity to:

• Birch Pollen (Betula verrucosa): Due to the similarity between the Mal d 1 protein and the Bet v 1 protein.
• Other Rosaceae Fruits: Including pears, peaches, cherries, and plums.
• Latex: Some patients with 'Latex-Fruit Syndrome' may react to apple proteins.

> Important: Your healthcare provider will evaluate your complete medical history before prescribing Malus Sylvestris Flower.

Malus Sylvestris Flower is classified as Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women.

• Diagnostic Testing: Should be postponed until after delivery to avoid any risk of systemic reaction.
• Immunotherapy: If a woman is already on a stable maintenance dose and becomes pregnant, the treatment is often continued but the dose is not increased. Starting new immunotherapy during pregnancy is strongly discouraged due to the risk of anaphylaxis-induced uterine contractions and fetal distress.

It is not known whether the allergenic proteins from Malus Sylvestris Flower are excreted in human milk. However, because these are large proteins that are likely digested in the infant's gut, the risk to the nursing infant is considered low. The primary concern is the mother's safety and the potential for a systemic reaction to affect her ability to breastfeed.

• Safety: Clinical trials have shown that skin testing is safe in children. However, the emotional and physical stress of the procedure should be considered.
• Efficacy: Immunotherapy is effective in children, but it is generally reserved for those with symptoms that are not well-controlled by environmental avoidance and standard medications.
• Growth: There is no evidence that allergenic extracts like Malus Sylvestris Flower affect growth or development in children.

• Reduced Reactivity: Patients over 65 often show smaller wheal diameters during skin testing, which can lead to under-diagnosis.
• Comorbidities: The presence of hypertension, coronary artery disease, or COPD in elderly patients makes the management of a systemic reaction significantly more complex.
• Polypharmacy: Elderly patients are more likely to be on medications (like beta-blockers or ACE inhibitors) that interact poorly with the extract or its emergency treatment.

No dosage adjustment is required for patients with renal impairment when using diagnostic extracts. For immunotherapy, clinical judgment is required, as these patients may have a reduced physiological reserve to handle systemic anaphylaxis.

There are no specific guidelines for hepatic impairment. Since the proteins are not metabolized by the liver's microsomal enzyme system, liver disease is not expected to significantly alter the pharmacology of the extract.

> Important: Special populations require individualized medical assessment.

Malus Sylvestris Flower extract functions as an immunological agonist. The primary mechanism involves the cross-linking of allergen-specific IgE antibodies bound to the high-affinity FceRI receptors on mast cells and basophils.

1. 1Sensitization Phase: In allergic individuals, B-cells have already produced IgE antibodies specific to Malus Sylvestris proteins (e.g., Mal d 1). These IgE molecules coat the surface of mast cells in the skin and mucous membranes.
2. 2Elicitation Phase: Upon administration of the extract, the multivalent allergens bind to multiple IgE molecules. This pulls the FceRI receptors together, initiating an intracellular signaling cascade involving tyrosine kinases (Syk and Lyn).
3. 3Mediator Release: This cascade leads to the influx of calcium and the exocytosis of pre-formed granules containing histamine, proteoglycans, and neutral proteases. It also triggers the 'de novo' synthesis of leukotrienes and cytokines, resulting in the characteristic allergic inflammation.

• Dose-Response: There is a clear dose-response relationship in skin testing; higher concentrations of the extract produce larger wheals, up to a saturation point.
• Time to Onset: The immediate (Type I) reaction occurs within 5 to 10 minutes and peaks at 15 to 20 minutes.
• Duration: The visible skin reaction typically fades within 1 to 2 hours, though a late-phase reaction (mediated by T-cells and eosinophils) can occur 6 to 24 hours later.

| Parameter | Value |

|---|---|

| Bioavailability | Low (Local administration) |

| Protein Binding | N/A (Binds to IgE receptors) |

| Half-life | Variable (Proteins degraded within hours) |

| Tmax | 15-20 minutes (for skin reaction) |

| Metabolism | Proteolytic degradation |

| Excretion | Renal (as peptide fragments) |

• Composition: A complex mixture of water-soluble proteins, glycoproteins, and polysaccharides.
• Key Allergens: Mal d 1 (17 kDa), Mal d 2 (thaumatin-like), Mal d 3 (non-specific lipid transfer protein), and Mal d 4 (profilin).
• Solubility: Highly soluble in aqueous solutions and glycerol-saline mixtures.

Malus Sylvestris Flower is a Non-Standardized Plant Allergenic Extract. It belongs to the broader therapeutic category of Allergenics, which includes other fruit extracts (e.g., Pyrus communis), pollen extracts (e.g., Phleum pratense), and venom extracts (e.g., Vespula spp.).